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Abstract
Purpose: The medical trainee perspective regarding the prior authorization process has not been previously assessed. Here we evaluate
the perceptions of radiation and medical oncology trainees regarding the prior authorization process and its effect on their training and
patient care.
Methods and Materials: A 12-question, nonincentivized, electronic national survey of radiation and medical oncology trainees at all
Accreditation Council for Graduate Medical Education accredited oncology programs was conducted. Participation, perspectives, and
experiences with the prior authorization process were assessed by Likert scale, free response, and multiple response selection.
Results: Between January and March of 2019, the survey was distributed to 1505 trainees at 76 institutions with responses from 174/
616 radiation (28.2%) and 139/889 medical oncology trainees (15.6%). The majority (69.2%) reported participating in the prior
authorization process (radiation: 78.2% vs medical: 57.6%; P < .01). Most trainees (71%) reported concern for decline in the quality of
patient care due to the prior authorization process. The majority of trainees (77.1%) reported decreased enthusiasm for work and
choice of profession, with a higher incidence in medical oncology trainees (83.1% vs 73.7%, P = .04). The most commonly
recommended modiﬁcations by trainees included that the insurance reviewer be in the same specialty as the ordering provider (87.7%),
providers be compensated for participation (82.7%), and turnaround time be more rapid (74.3%).
Conclusions: These data indicate that trainees in US oncology programs are active participants in the prior authorization process and
report that prior authorization approvals negatively inﬂuence their medical training and the quality of patient care. Additional efforts
to revise the insurance approval process are warranted.
© 2021 The Author(s). Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Health care spending in the United States is projected
to grow at a rate of 6% annually and by 2026 will constitute 19.7% of the annual gross domestic product.1 To stem
these rising costs and improve proﬁtability, insurance
companies have implemented the prior authorization process, which requires providers to obtain preapproval for
certain services rendered to qualify for payment.2
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However, physicians have increasingly expressed concerns
surrounding the prior authorization process as highlighted
in the 2017 and 2018 American Medical Association surveys, in which providers criticized prior authorizations as
being inefﬁcient and negatively affecting patient
outcomes.3
More recently, reports have highlighted instances in
which prior authorizations have been inadequately
reviewed within the context of novel therapies that may be
available for treatment.4 These reports are particularly troubling for the ﬁeld of oncology, wherein the standard of care
changes frequently due to advances in imaging, systemic
therapies, and radiation therapy, all of which are subject to
the prior authorization process. Though the perception of
the prior authorization process has been largely negative
among oncologists, its effect on oncology trainees, their
education, and their attitudes is unknown. Given the recent
emphasis in reducing house staff work hours, it is critical
that their responsibilities prioritize activities that are educational and provide training for independent practice.5 The
aim of this study was to evaluate the perceptions of residents
and/or fellows in radiation oncology and medical oncology
regarding the prior authorization process, and to determine
how it has affected their training and the care they provide
for patients.

Methods and Materials
In January 2019, a 12-question electronic survey was distributed via email invitation to radiation oncology residents
in all Accreditation Council for Graduate Medical Education (ACGME)−accredited programs and to medical oncology fellows at the corresponding institutions. Questions
assessed trainee participation in prior authorization, trainee
impressions on the prior authorization process, suggestions
for prior authorization process improvement, and participant demographics. Survey questions were written by an
attending physician and 2 resident physicians and are available for review in Table 1. This study was deemed exempt
by our institutional review board.
Anonymous, nonincentivized, and voluntary surveys
were distributed via SurveyMonkey.com. The goal
response rate was 20% with plans to send 2 reminder
emails at 2-week intervals and close the survey 2 weeks
after the ﬁnal reminder. This response rate was selected as
survey response was anticipated to be less than that of
society-endorsed surveys due to high demand on trainee
time and survey fatigue.6,7 Whereas the merit and potential for impact of investigator initiated surveys are largely
unknown, societal surveys appear to have the support of
the society’s leadership and potential to drive change in a
given organization. Descriptive statistics, tests of proportions, and the Fisher exact test were used for statistical
analysis. A 2-sided P < .05 was considered statistically signiﬁcant.
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Results
The survey was distributed to 1505 trainees at 76 institutions, with 313 individual responders, including 174 of
616 radiation oncology trainees and 139 of 889 medical
oncology trainees (28.2% vs 15.6%, P < .01). Questions
and responses from the survey are provided in Table 1.
Most respondents (69%) reported participating in
prior authorizations, though rates differed by radiation
oncology and medical oncology specialties (78.2% vs
57.6%, P < .01). Frequency of prior authorizations was
also higher among radiation oncology trainees, with 58%
reporting >2 appeals per month compared with 29.4% of
medical oncology trainees (P < .01). A signiﬁcant portion
of trainees spend more than 30 minutes on each appeal
(40%). In regard to the peer-to-peer process, 55% of trainees indicated that the reviewing physician did not have
proper credentials to accurately assess the clinical scenario
when denying the claim. Though most respondents
(71.7%) reported successful appeals >50% of the time,
74.6% of trainees stated that issues with prior authorizations would lead to changes in the recommended treatment “sometimes” or “often,” which was similar by
specialty (radiation oncology: 74.4% vs medical oncology:
75.0%, P = .99).
Trainees shared concerns regarding the effects of prior
authorization on patient care, with nearly all (92.4%) stating
that prior authorizations “increased the time it takes for
patients to receive care.” Accordingly, 75.6% of trainees
reported “somewhat” or “strongly” decreased enthusiasm
for work and choice of profession, though this sentiment
was more common among medical oncology trainees compared with radiation oncology trainees (83.1% vs 73.7%,
P = .04). As many as 67% of trainees reported that the prior
authorization process negatively affected their clinical training and education. The most commonly recommended
modiﬁcation by trainees included the suggestion that the
insurance reviewer be in the same specialty as the ordering
provider (87.7%). This was followed by recommending that
providers be compensated for the prior authorization process (82%), the peer reviewer have more appropriate medical credentials (69%), and the prior authorization process
be more timely (74%).

Discussion
This is the ﬁrst study to assess oncology trainee perspective on the prior authorization process. We found
that a high percentage of trainees are involved in the prior
authorization and peer-to-peer process but report that it
negatively affects their clinical education and training as
well as their enthusiasm for their chosen profession.
Given the limited time during training to learning clinical
and research skills, especially in an era of reduced duty

Survey questions and responses
Medical oncology
n = 139

1. Do you conduct or participate in appeals and
peer-to-peer reviews for insurance denial of
medications, imaging, or procedures you or
your team prescribed?
2. How often do you participate in the appeals
process with insurance companies, either by
paper or phone? (times per mo)
3. On average, how much time do you spend on
each appeals process (including preparation
time, written appeals, and peer-to-peer
reviews)? (min)
4. How often do you overturn insurance denials
with appeals? (percent)
5. The physician I speak to during peer-to-peer
reviews has appropriate qualiﬁcations to
decline or approve the treatment, imaging, or
laboratory testing in question.*

Radiation oncology
n = 174

Yes
80 (57%)

Total
N = 313

No

Yes

No

Yes

No

59 (42%)

136 (78%)

38 (22%)

216 (69%)

97 (31%)

1-2

3-5

6-10

54 (71%)

13 (17%)

9 (12%)

>10
0

1-2

3-5

6-10

>10

1-2

3-5

6-10

>10

57 (44%)

44 (34%)

23 (18%)

5 (4%)

111 (54%)

57 (28%)

32 (16%)

5 (2%)

<5

5-14

15-29

≥30

<5

5-14

15-29

≥30

<5

5-14

15-29

≥30

2 (3%)

15 (20%)

27 (36%)

32 (43%)

1 (1%)

37 (29%)

42 (33%)

49 (38%)

3 (1%)

52 (25%)

69 (34%)

81 (40%)

<25

25-49

50-75

>75

<25

25-49

50-75

>75

<25

25-49

50-75

>75

6 (8%)

19 (25%)

31 (41%)

20 (26%)

13 (10%)

20 (16%)

48 (37%)

48 (37%)

19 (9%)

39 (19%)

79 (39%)

68 (33%)

+2

+1

0

−1

−2

+2

0

9 (12%)

23 (30%)

26 (34%)

18 (24%)

1 (1%)

0

−1

−2

+2

+1

0

−1

−2

33 (26%)

44 (24%)

26 (20%)

1 (0%)

34 (17%)

56 (27%)

70 (34%)

44 (21%)

+1
25 (19%)

+2

+1

0

−1

−2

+2

+1

0

−1

−2

+2

+1

0

−1

−2

0

16 (21%)

41 (54%)

13 (17%)

6 (8%)

0

23 (18%)

73 (57%)

29 (22%)

4 (3%)

0

39 (19%)

114 (56%)

42 (20%)

10 (5%)

8. The peer-to-peer process has changed the
enthusiasm I feel about my work and choice
of profession in the following ways:z

+2

+1

0

−1

−2

+2

+1

0

−1

−2

+2

+1

0

−1

−2

0

0

13 (18%)

37 (51%)

23 (32%)

0

0

35 (28%)

66 (53%)

23 (19%)

0

0

48 (24%)

103 (52%)

46 (23%)

+2

+1

0

−1

−2

+2

+1

0

−1

−2

+2

+1

0

−1

−2

1 (1%)

7 (10%)

18 (25%)

24 (33%)

23 (32%)

1 (1%)

18 (15%)

20 (16%)

55 (44%)

30 (24%)

2 (1%)

25 (13%)

38 (19%)

79 (40%)

53 (27%)

10. The time and effort preparing for and performing appeals and peer-to-peer reviews (ie,
reviewing pertinent literature, discussing case
with attending physician) have the following
impact on my clinical education and training.x
7. In your opinion, how has the appeals and
peer-to-peer process changed the following
regarding patient care (check all that apply)?
(total only)

Quality of care

Frequency of appropriate care

Decreased

Increased

Decreased

Increased

Decreased

Increased

141 (72%)

4 (2%)

30 (15%)

64 (32%)

4 (2%)

182 (92%)

113 (57%)

6 (3%)

None

Same specialty
reviewer

0
PGY-0031
1 (1%)

12. In what region of the United States do you
train?

Time to receive care

Increased

9. What modiﬁcation(s) would you make to the
current insurance appeal system, if any (check
all that apply)? (total only)
11. What is your level of training?

Cost of care

Decreased

Northeast
75 (38%)

Compensation for
prior authorization

Increased credentials
for peer-to-peer

More rapid
decisions

170 (86%)

163 (82%)

135 (69%)

PGY-2

PGY-3

PGY-4

PGY-5

PGY-6

146 (74%)
Other

13 (7%)

32 (16%)

61 (31%)

58 (29%)

30 (15%)

2 (1%)

South

Midwest

West

41 (21%)

56 (28%)

25 (13%)

Abbreviation: PGY = postgraduate year.
* Strongly agree (+ 2), somewhat agree (+ 1), neutral (0), somewhat disagree (−1), strongly disagree (−2).
y Always (+ 2), often (+ 1), sometimes (0), rarely (−1), never (−2).
z Strongly increased (+ 2), somewhat increased (+ 1), neutral (0), somewhat decreased (−1), strongly decreased (−2).
x Strongly contribute/improve (+ 2), somewhat contribute/improve (+ 1), neutral (0), somewhat detract/prevent (−1), strongly detract/prevent (−2).
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6. How often do issues with the appeals process
lead to changing the recommended course of
treatment?y
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hours, this is concerning. Although not speciﬁcally
assessed in this survey, this negative impact on education
and enthusiasm may be associated with an increase in
trainee burnout as well.8,9
The ACGME has long maintained that trainees actively
participate in all aspects of patient care.10 As practicing
physicians are ultimately responsible for prescribing and
directing a patient’s care, the ability to navigate billing and
prior authorization hurdles is critical to a physician’s clinical acumen. This is perhaps one of many reasons trainees
have participated in the prior authorization process. In our
study, we found that trainees in both radiation and medical
oncology are actively involved in the prior authorization
process, with 69% reporting participation and 82% of this
participating group completing 1 to 5 appeals per month.
Importantly, these efforts are perceived by trainees as
decreasing the quality of patient care (72%) and frequency
with which appropriate care is delivered (57%). Although
the majority of respondents (72%) reported successful
appeals >50% of the time, 19% of respondents reported
that issues with the prior authorization process will “often”
change the intended treatment course.
In both the American Medical Association survey and
this survey, 92% of participants reported prior authorization-associated delays in patient care.3 This ﬁnding is in
line with published data that prior authorizations delayed
initiation of radiation therapy by an average of 3 weeks in
patients recommended to undergo proton beam therapy.11 A similar study found that as many as 34% of such
patients are initially denied proton treatment,12 which
suggests that the prior authorization process disproportionately affects innovative treatment modalities. This is
also observed in the ﬁeld of medical oncology, where a
study evaluating prior authorizations in a high-volume
breast-oncology clinic found that 26.5% of all prior
authorizations tracked were for palbociclib,13 a novel
therapy for hormone-sensitive breast cancers. Prior
authorization denials for these services are likely a major
reason why trainees report changes in the recommended
treatment plan for these patients up to 75% of the time.
This is especially signiﬁcant because treatment delays
have been associated poorer outcomes in multiple cancer
types.14-16 Further, the efforts of trainees and physicians
to perform the prior authorization process are not
tracked, credited, or ﬁnancially reimbursed. This also
includes the efforts of dosimetrists and physicists to produce comparison plans for insurance companies to demonstrate the need for more complex radiation techniques.
Trainees do identify several possible avenues for
improving the prior authorization process. In this survey,
nearly 90% of participants suggested that that insurance
reviewers be in the same specialty as the ordering provider, and 75% supported more rapid turnaround times.
Physician compensation for time and effort spent on the
prior authorization process may disincentivize insurance
companies from denying claims based on algorithms or
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the decision making of physicians who lack training in
the relevant ﬁeld. Oversight to ensure that this compensation is not abused would be required.
Cancer care is generally categorized as nonemergent by
insurance companies, with company policy permitting up
to weeks for appeal decisions after peer-to-peer discussion, and potentially no option for further discussion during this arbitration period. In a patient population where
certain diagnoses can result in a life expectancy of less
than a year, up to 10% of that remaining time could
potentially be spent waiting for approval to pursue lifeextending or life-saving therapies. This can result in high
patient and physician concern and selection of less ideal
treatments that are approved by insurance providers.
The prior authorization issue is not unique to oncology.
Published data indicate it hinders delivery of patient care in
psychiatry,17 dermatology,18 endocrinology,19 and gastroenterology,20 to cite a few examples. Changes are necessary
so that the decision making of trained medical professionals
is not governed by reimbursement guidelines that are not
infrequently written and executed by those without pertinent medical expertise. One potential solution would be
transitioning authority to regulate inappropriate medical
practice (ie, excessive diagnostics and procedures) from
insurance providers to the medical boards that grant licensure to their practicing members. The standing policy
would be that all orders are covered by the insurance provider. If the reimbursing body has concerns for inappropriate practice, it can ﬁle a complaint to the physician licensing
board. Patient diagnostic study and treatment orders would
not be affected until a ﬁnal ﬁnding of inappropriate use was
determined. This would allow a system where medical practice was reviewed by credentialing physician bodies, not
insurance policy rubrics, without delaying patient care. The
American Society of Clinical Oncology Value Framework is
an important example of oncology leadership helping
physicians exercise cost conscientious, patient-speciﬁc
care.21 However, in our current environment, the ultimate
arbitrator of care delivered still remains the reimbursing
entity.
The response rate of this study, while limited, is not
too far from previously published studies assessing medical house staff and oncologists.6,7,22 Given the multiple
demands on time that medical trainees face, responding
to surveys may not be frequently prioritized. Recent data
demonstrate that surveys with lower response rates may
be as accurate or more accurate compared with those
with higher response rates.23 It is true that these ﬁndings
may be biased toward a cohort of trainees who have the
most extreme experiences with the prior authorization
process. However, it is possible that this is truly an evenly
distributed response group and that frequent email
reminders may have negatively inﬂuenced the quality of
the data.24,25 Further, the authors propose that similar
concerns voiced in 20% of a residency program via an
ACGME residency evaluation survey would likely result
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in immediate department and program director response.
Because the responses were anonymous, it was not possible to link rate of participation in prior authorization to
speciﬁc technology such as proton therapy or adaptive
radiation therapy. We anticipate that centers with treatment modalities that are considered experimental in certain disease settings would undergo more frequent prior
authorization processes. While these data may be limited
to a hypothesis generating study, they identify a potential
area of improvement as program directors work to
address oncology program education and quality of life
issues.

Conclusion
The authors recognize that meaningful reform to the
prior authorization process will take time. Despite its
challenges, prior authorization remains an integral component of the health care system. Until signiﬁcant reform
is achieved, trainees should maintain active participation
because it is an integral component of patient care and it
is highly likely that they will also engage in the prior
authorization process as practicing physicians. Program
directors may meet with trainees to discuss novel
approaches to the prior authorization process to increase
appeal success rate and decrease time allotted to each
appeal (eg, shared templates for appeal letters, discussing
data with faculty before peer-to-peer call, and reviewing
provider approval criteria for service speciﬁc diagnoses
and treatments). In the meantime, we urge clinical and
academic societies to advocate for tangible reform so that
this process does not negatively affect medical education
and clinical training.
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